Lange, A., Jaskula, E., Lange, J., Dworacki, G., Nowak, D., Simiczyjew, A., . . . Sedzimirska, M. (2018). Correction: The sorafenib anti-relapse effect after alloHSCT is associated with heightened alloreactivity and accumulation of CD8+PD-1+ (CD279+) lymphocytes in marrow. PLoS One.

Lange, Andrzej, Emilia Jaskula, Janusz Lange, Grzegorz Dworacki, Dorota Nowak, Aleksandra Simiczyjew, Monika Mordak-Domagala, and Mariola Sedzimirska. "Correction: The Sorafenib Anti-relapse Effect After AlloHSCT Is Associated With Heightened Alloreactivity and Accumulation of CD8+PD-1+ (CD279+) Lymphocytes in Marrow." PLoS One 2018.

Lange, Andrzej, et al. "Correction: The Sorafenib Anti-relapse Effect After AlloHSCT Is Associated With Heightened Alloreactivity and Accumulation of CD8+PD-1+ (CD279+) Lymphocytes in Marrow." PLoS One 2018.